Evaluation of in vitro biological activity of O-alkylated hydroxamic derivatives of some nonsteroidal anti-inflammatory drugs

Anticancer Research

Volumn 30, Issue 10, 2010, Pages 3987-3994

  Pavelić, Sandra Kraljević ^a   Sedić, Mirela ^b   Poznić, Miroslav ^b   Rajić, Zrinka ^c   Zorc, Branka ^c   Pavelić, Krešimir ^a   Balzarini, Jan ^d   Mintas, Mladen ^e  

^a University of Rijeka   (Croatia)

^b RUDER BO KOVI INSTITUTE   (Croatia)

^c UNIVERSITY OF ZAGREB   (Croatia)

^d REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^e UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Akt signalling; Apoptosis; Cell cycle; Cytostatic activity; Cytotoxicity; Human pancreatic cancer; Hydroxamic acids; Nonsteroidal anti inflammatory drugs (NSAID)

Indexed keywords

1 ( 4 CHLOROBENZOYL) 2 METHYL N METHOXY 5 METHOXY 1H INDOL 3 ACETAMIDE; ACETAMIDE DERIVATIVE; BENZENEACETAMIDE DERIVATIVE; CASPASE 3; HYDROXAMIC ACID DERIVATIVE; N BENZYLOXY 2 ( 3 BENZOYLPHENYL)PROPANAMIDE; N ETHOXY 1 ( 4 CHLOROBENZOYL) 2 METHYL 5 METHOXY 1H INDOL 3 ACETAMIDE; N ETHOXY 2 ( 3 BENZOYLPHENYL)PROPANAMIDE; N ETHOXY 2 ( 3 PHENOXYPHENYL)PROPANAMIDE; N ETHOXY 2 ( 4 ISOBUTYLPHENYL)PROPANAMIDE; N ETHOXY 2 [ 2 ( 2,6 DICHLOROPHENYL)AMINO]BENZENEACETAMIDE; N HYDROXY 2 ( 3 BENZYLPHENYL)PROPANAMIDE; N METHOXY 2 [ 2 ( 2,6 DICHLOROPHENYL)AMINO]BENZENEACETAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG;

ALKYLATION; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOSTASIS; DRUG CYTOTOXICITY; DRUG SYNTHESIS; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; HELA CELLS; HUMANS; HYDROXAMIC ACIDS; LEUKEMIA L1210; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78650239891     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Thun MJ, Henley SJ and Patrono C: Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94: 252-266, 2002.
2. Muri EM, Nieto MJ, Sindelar RD and Williamson JS: Hydroxamic acids as pharmacological agents. Curr Med Chem 9: 1631-1653, 2002.
3. Unangst PC, Connor DT, Cetenko WA, Sorenson RJ, Kostlan CR, Sircar JC, Wright CD, Schrier DJ and Dyer RD: Synthesis and biological evaluation of 5-[[3,5-bis(1,1-dimethylethyl)- 4-hydroxyphenyl]methylene]oxazoles, -thiazoles, and -imidazoles: novel dual 5-lipoxygenase and cyclooxygenase inhibitors with antiinflammatory activity. J Med Chem 37: 322-328, 1994.
4. Orzalesi G, Selleri R, Caldini O, Volpato I, Innocenti F, Colome J, Sacristan A and Varez G: Ibuproxam and Ibuprofen. A pharmacological comparison. Arzneimittelforschung 27: 1006-1012, 1977.
5. Rajic Z, Butula I, Zorc B, Kraljevic Pavelic S, Hock K, Pavelic K, Naesens L, De Clercq E, Balzarini J, Przyborowska M, Ossowski T and Mintas M: Cytostatic and antiviral activity evaluations of hydroxamic derivatives of some non-steroidal anti-inflammatory drugs. Chem Biol Drug Des 73: 328-338, 2009.
6. Rajić Z, Perković I, Butula I, Zorc B, Hadjipavlou-Litina D, Pontiki E, Pepeljnjak S and Kosalec I: Synthesis and biological evaluation of O-methyl and O-ethyl NSAID hydroxamic acids. J Enzyme Inhib Med Chem 24: 1179-1187, 2009.
7. Printsevskaya SS, Solovieva SE, Olsufyeva EN, Mirchink EP, Isakova EB, De Clercq E, Balzarini J and Preobrazhenskaya MN: Structure-activity relationship studies of a series of antiviral and antibacterial aglycon derivatives of the glycopeptide antibiotics vancomycin, eremomycin, and dechloroeremomycin. J Med Chem 48: 3885-3890, 2005.
8. 13C NMR study, cytostatic and antiviral evaluation. Bioorg Med Chem 13: 131-139, 2005.
9. Kraljevic S, Stambrook PJ and Pavelic K: Accelerating drug discovery. EMBO Rep 5: 837-842, 2004.
10. Kraljevic S, Sedic M, Scott M, Gehrig P, Schlapbach R and Pavelic K: Casting light on molecular events underlying anticancer drug treatment: what can be seen from the proteomics point of view? Cancer Treat Rev 32: 619-629, 2006.
11. Liu S, Bishop WR and Liu M: Differential effects of cell cycle regulatory protein p21(WAF1/Cip1) on apoptosis and sensitivity to cancer chemotherapy. Drug Resist Updat 6: 183-195, 2003.
12. Yoshikawa H, Nagashima M, Khan MA, McMenamin MG, Hagiwara K and Harris CC: Mutational analysis of p73 and p53 in human cancer cell lines. Oncogene 18: 3415-3421, 1999.
13. Mortenson MM, Galante JG, Gilad O, Schlieman MG, Virudachalam S, Kung HJ and Bold RJ: BCL-2 functions as an activator of the AKT signaling pathway in pancreatic cancer. J Cell Biochem 102: 1171-1179, 2007.
14. Schlieman MG, Fahy BN, Ramsamooj R, Beckett L and Bold RJ: Incidence, mechanism and prognostic value of activated AKT in pancreatic cancer. Br J Cancer 89: 2110-2115, 2003.
15. Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB and McConkey DJ: Inhibition of the phosphatidylinositol 3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther 1: 989-997, 2002.
16. Fahy BN, Schlieman M, Virudachalam S and Bold RJ: AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2. Br J Cancer 89: 391-397, 2003.
17. Huo JX, Metz SA and Li GD: p53-independent induction of p21(wafl/cipl) contributes to the activation of caspases in GTP-depletion-induced apoptosis of insulin-secreting cells. Cell Death Differ 11: 99-109, 2004.
18. Kandel ES and Hay N: The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp Cell Res 253: 210-229, 1999.
19. Liu X, Shi Y, Woods KW, Hessler P, Kroeger P, Wilsbacher J, Wang J, Wang JY, Li C, Li Q, Rosenberg SH, Giranda VL and Luo Y: Akt inhibitor a-443654 interferes with mitotic progression by regulating aurora a kinase expression. Neoplasia 10: 828-837, 2008.
20. Tang HL, Yuen KL, Tang HM and Fung MC: Reversibility of apoptosis in cancer cells. Br J Cancer 100: 118-122, 2009.
21. Yang JY, Michod D, Walicki J, Murphy BM, Kasibhatla S, Martin SJ and Widmann C: Partial cleavage of RasGAP by caspases is required for cell survival in mild stress conditions. Mol Cell Biol 24: 10425-10436, 2004.
22. Yang JY, Walicki J, Michod D, Dubuis G and Widmann C: Impaired Akt activity down-modulation, caspase-3 activation, and apoptosis in cells expressing a caspase-resistant mutant of RasGAP at position 157. Mol Biol Cell 16: 3511-3520, 2005.
23. Yang JY and Widmann C: Antiapoptotic signaling generated by caspase-induced cleavage of RasGAP. Mol Cell Biol 21: 5346-5358, 2001.